The upcoming report from Accuray (ARAY) is expected to reveal quarterly loss of $0.07 per share, indicating a decline of 250% compared to the year-ago period. Analysts forecast revenues of $107.11 million, representing a decrease of 6.7% year over year.Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Before a company announces its earnings, it is essential ...

Accuray Incorporated (ARAY) recently announced that the Providence Swedish Radiosurgery Center in Seattle, WA, is purchasing the latest generation CyberKnife S7 System. This purchase will be the hospital's second CyberKnife radiation delivery device purchase.With the purchase of the latest CyberKnife, the center is expecting to enhance its cancer treatment capabilities. The robotic nature of the device will also enable precision and accuracy, making it a perfect option for treating neurologic problems. This ...

New System Will Play a Key Role in Delivering Radiation Treatments in One of the Largest Cancer Facilities in Washington StateMADISON, Wis., Jan. 25, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Providence Swedish Radiosurgery Center in Seattle, Washington is enhancing its cancer treatment capabilities with the purchase of the latest generation CyberKnife® S7™ System, the hospital's second CyberKnife radiation delivery device purchase. The precision and accuracy enabled ...

MADISON, Wis., Jan. 16, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the second quarter of fiscal year 2024, ended December 31, 2023, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on January 31, 2024. The conference call dial-in numbers are (833) 316-0563 (USA) or (412) 317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one we ...

Accuray Incorporated (ARAY) is well-poised for growth in the coming quarters, courtesy of continued solid demand for its products. The optimism led by the first-quarter fiscal 2024 performance and potential in Precision Treatment Planning System (TPS) are expected to contribute further. However, overdependence on technologies and macroeconomic instability persist.Over the past year, this Zacks Rank #3 (Hold) stock has gained 33.8% against the 0.1% decline of the industry. The S&P 500 has witnessed 21.9% gro ...

Financial Data and Key Metrics - Global revenue grew by 8% year-over-year, with product revenue increasing by 17% year-over-year [8] - Order backlog stood at $489 million, representing more than 2x fiscal year 2023 product revenue [8] - Installed base of customers grew to 1,040 systems, a 5% year-over-year increase [9] - Net revenue for Q1 was $104 million, up 8% from the prior year, with product revenue at $53 million, up 17% [22][23] - Service revenue was $51 million, down 1% from the prior year [23] - Gross margin for the quarter was 38%, up from 35.9% in the prior year [25] - Adjusted EBITDA for the quarter was $6.5 million, compared to $1.9 million in the prior year [25] Business Line Performance - Continued customer adoption of CyberKnife, Radixact, and TomoTherapy platforms, driven by demand for advanced radiotherapy treatments [7] - New product innovations showcased at ASTRO, including VitalHold, Alliance-Plus, and Cenos online adaptive capability [10][11] - Cenos, leveraging AI for adaptive radiotherapy, is expected to be available for customer orders in spring 2024 [12] Market Performance - Strong performance in the U.S. and China, with regulatory clearance for the Tomo C platform in China, targeting a $600 million annual market opportunity [14][15] - Introduction of Helix, a value segment product, targeting high-potential emerging markets like India [16] - Strategic win at the Royal Marsden in the U.K., reinforcing the company's brand and market position [17][18] Strategic Direction and Industry Competition - Focus on achieving above-market revenue growth through innovation and commercial execution, expanding margins, and leveraging strategic partnerships [6] - Emphasis on improving patient access in underpenetrated global markets, particularly in China and India [14][16] - Competitive differentiation through comprehensive adaptive tools like Cenos, expected to increase win rates and upgrade the aged TomoTherapy installed base [12] Management Commentary on Operating Environment and Future Outlook - Positive outlook for radiation oncology, supported by technology advancements and clinical data, despite short-term headwinds in the U.S. [13] - Restructuring actions, including a 6% workforce reduction, aimed at simplifying the organization and improving operational efficiency [19] - Investments in commercial and customer support resources to maximize product innovations and market position [20] Other Important Information - Participation in the ASTRO conference, driving interest in new product innovations and showcasing the company's leadership in radiation oncology [10][17] - Launch of Accuray Financial Services to provide flexible financing options for capital equipment acquisition [10] - Enhanced executive team with new leadership in R&D, global service, and IT, leveraging experience from leading companies in the sector [21] Q&A Session Summary Question: Guidance and Order Funnel - The company remains cautiously optimistic, with strong Q1 performance but conservative guidance due to extended sales cycles in the U.S. and anti-corruption campaigns in China [30][31] Question: China Tomo C Opportunity - Tomo C approval came earlier than expected, with strong demand anticipated in the Type B market segment in China [32][33] - Revenue from Tomo C is expected to start contributing in Q4, with shipments to customers beginning in fiscal Q4 [34] Question: Inflation and Pricing Environment - Inflation remains a challenge, with a $2.5 million headwind in Q1, though supplier price increases have slowed [36][37] Question: Reimbursement Changes - Positive movement in U.S. reimbursement models, with ASTRO proposing a model that favors shorter-duration treatments like SBRT, expected to take over a year to implement [38][39] Question: Cenos Online Adaptive Solution - Strong customer interest in Cenos, with 510(k) pending and expected availability for orders in Q3 [42][43] Question: Helix Market Potential in India - India represents a $100 million to $150 million annual market opportunity for the Helix product, targeting high-growth emerging markets [44][45]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value per share ARAY The Nasdaq Stock Market LLC FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33301 ACCURAY INCORPORATED (Exact name of registrant as specified in its charter) DELAWARE 20-8370041 (State or Other J ...

Accuray Incorporated (NASDAQ:ARAY) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Jesse Chew - Chief Legal Officer Suzanne Winter - President and CEO Ali Pervaiz - CFO Conference Call Participants Josh Jennings - Cowen Young Li - Jefferies Marie Thibault - BTIG Aaron Wukmir - Lake Street Capital Markets Neil Chatterji - B. Riley FBR Operator Hello and welcome to the Accuray Fourth Quarter and Fiscal 2023 Financial Results Conference Call. All participants will be in listen-o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-33301 ACCURAY INCORPORATED (Exact name of registrant as specified in its charter) Delaware 20-8370041 (State or other jurisdiction of inco ...